Amarantus Bioscience Holdings Inc (AMBS)

[breezy1]

"On LymPro: Following the announcement of positive analytical performance on LymPro last October, Amarantus is pushing forward with a 7-year follow-up analysis of the 88 patients studied in the Phase 1 trial. This will be an incredibly important longitudinal analysis for the validation of LymPro and help management secure a development and commercialization partnership once completed. The next step is to establish long-term analytical performance to support commercial launch in 2015 (note: management guidance is "second half of 2014")."

End Quote from below reference:



http://seekingalpha.com/article/2027661-new-cash-to-help-drive-amarantus-pipeline

Partnership is next - Hold on to the Rocket Ship